American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

被引：1078

作者：

Saag, Kenneth G. ^{[2
]}

Teng, Gim Gee ^{[2
]}

Patkar, Nivedita M. ^{[2
]}

Anuntiyo, Jeremy ^{[1
]}

Finney, Catherine ^{[1
,6
]}

Curtis, Jeffrey R. ^{[2
]}

Paulus, Harold E. ^{[1
]}

Mudano, Amy ^{[2
]}

Pisu, Maria ^{[2
]}

Elkins-Melton, Mary ^{[2
]}

Outman, Ryan ^{[2
]}

Allison, Jeroan J. ^{[2
]}

Almazor, Maria Suarez ^{[3
]}

Bridges, S. Louis, Jr. ^{[2
]}

Chatham, W. Winn ^{[2
]}

Hochberg, Marc ^{[4
]}

Maclean, Catherine ^{[1
,5
]}

Mikuls, Ted ^{[7
]}

Moreland, Larry W. ^{[8
]}

O'Dell, James ^{[1
,5
,6
]}

Turkiewicz, Anthony M. ^{[2
]}

Furst, Daniel E. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA 90095 USA

[2] Univ Alabama, Tuscaloosa, AL 35487 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Univ Maryland, Baltimore, MD 21201 USA

[5] RAND Corp, Santa Monica, CA USA

[6] W Los Angeles VAMC, Los Angeles, CA USA

[7] Univ Nebraska, Omaha, NE 68182 USA

[8] Univ Pittsburgh, Pittsburgh, PA USA

来源：

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2008年 / 59卷 / 06期

关键词：

D O I：

10.1002/art.23721

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.

引用

页码：762 / 784

页数：23

共 265 条

[81] Franz N, 2001, ADHES AGE, V44, P60
[82] THE RELATIVE TOXICITY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
FRIES, JF
WILLIAMS, CA
RAMEY, D
BLOCH, DA
[J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (03): : 297 - 306
[83] Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery
Fuerst, Martin
Moehl, Henrike
Baumgaertel, Kerstin
Ruether, Wolfgang
[J]. RHEUMATOLOGY INTERNATIONAL, 2006, 26 (12) : 1138 - 1142
[84] FURST DE, 1989, J RHEUMATOL, V16, P313
[85] Furst DE, 2003, J RHEUMATOL, V30, P2563
[86] Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease
Galvan, Vicente Giner
Oltra, Maria Rosa
Rueda, Diego
Esteban, Maria Jose
Redon, Josep
[J]. CLINICAL RHEUMATOLOGY, 2007, 26 (06) : 971 - 972
[87] Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
Geborek, P
Bladström, A
Turesson, C
Gulfe, A
Petersson, IF
Saxne, T
Olsson, H
Jacobsson, LTH
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (05) : 699 - 703
[88] Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden
Geborek, P
Crnkic, M
Petersson, IF
Saxne, T
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (09) : 793 - 798
[89] Genant HK, 2006, ANN RHEUM DIS, V65, P57
[90] Genovese MC, 2005, J RHEUMATOL, V32, P1232

← 4 5 6 7 8 9 10 11 12 13 →